bisphosphonates are the mainstay of treatment of Paget's disease
lead to inhibition of bone resorption
bind to calcium hydroxyapatite - leads to prevention of bone turnover
cellular effects - inhibition of osteoclast function, induction of apoptosis, reduction of production and activity of bone-remodelling units
routes and dosages vary with respect to different bisphosphonates
usually they are poorly absorbed from the gastrointestinal tract
oral drugs should be taken on an empty stomach at least half an hour before the intake of food or drink (1)
disodium etidronate was the first bisphosphonate to be used in the management of Paget's disease. However this drug may be associated with bone demineralisation and is relatively ineffective and second- and third- generation bisphosphonates have been developed
all of the second- and third- generation bisphosponates lead to (1):
a reduction in indices of bone turnover in 80%
result in a biochemical remission in 50-75% of patients after a single course of treatment
result in new bone formation with a lamellar pattern
these bisphosphonates rarely result in bone mineralisation abnormalities (2)
these drugs should be prescribed only following consultation of their respective summary of drug characteristics
in general, treatment should be with an oral second- or third- generation bisphosphonate in the initial management of Paget's disease requiring treatment; the use of intravenous therapy may be indicated if there oral therapy is ineffective; neurological complications are also an indication for intravenous therapy (3)
newer drugs such as zoledronate has been shown to be the most potent drug in the bisphophnate family with profound suppression of disease activity (2)
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.